See More StocksHome

CMMB

Chemomab Therapeutics Ltd DRC

Show Trading View Graph

Mentions (24Hr)

0

-100.00% Today

Reddit Posts

β€’r/pennystocksβ€’See Post

Chemomab $CMMB - DD to read for the weekend - Great potential

β€’r/pennystocksβ€’See Post

LIST OF MY STRONGEST $2 AND UNDER "LOW RADAR" VALUE STOCKS WITH GOOD ENTRIES FOR 2026!

β€’r/pennystocksβ€’See Post

Chemomab Therapeutics Ltd.(CMMB)

β€’r/Shortsqueezeβ€’See Post

CMMB bought the dip for a swing. Lot of good news of late. Shorts will cover

β€’r/Shortsqueezeβ€’See Post

CMMB bought the dip for a swing. Lot of good news of late. Shorts will cover

β€’r/WallStreetbetsELITEβ€’See Post

πŸ’°πŸ’°πŸ’°Good morning! #premarket #watchlist 01/03 $HZN -Announces Agreement with First Brands Group (+330%), $JSPR -Announces Positive Clinical Data from a Phase I/II Trial(+100%), $CMMB -Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomark (+40%)

β€’r/Shortsqueezeβ€’See Post

WHAT HAPPENED WITH $CMMB ?

Mentions

My AI Slop Analysis: $CMMB β€” The Most Interesting Merger Arb Nobody Is Talking About (NFA, I'm a degenerate with a spreadsheet) Let me tell you about a deal sitting in plain sight where you're paying $1.93 for something worth $6.08 if it closes, and roughly $1.10 if it doesn't. That's a 215% upside against a 43% downside, and the crowd has completely ignored it because the ticker is an Israeli clinical-stage biotech nobody has heard of and the merger partner is a private AI company that sounds like it was named by a startup generator. Stick with me. What CMMB is and why it ended up here Chemomab Therapeutics is what happens when legitimate science meets a market cap that simply cannot sustain a clinical program. They've been quietly bleeding shareholders through shelf offerings since 2024 β€” not dramatic, just a slow, dignified financial dying β€” and somewhere in the middle of that, they did a 4-to-1 ADS consolidation, which is a reverse split for people who want to describe it more politely. By mid-2025 the standalone trajectory was a straight line toward zero. The company had $8 million in cash, burns roughly $7 million a year, and was staring down a wall somewhere around Q1 2027 where the options would have been: raise more money and dilute everyone again, find a partner, or quietly fold. They chose find a partner. It was the only decision that made any sense. The drug, which is where this gets interesting Their sole asset is nebokitug, a monoclonal antibody that blocks CCL24 β€” a protein that drives both inflammation and fibrosis in a class of diseases where the body slowly and irreversibly scars itself from the inside. They ran a Phase 2 trial called SPRING in primary sclerosing cholangitis, which is one of those rare, progressive, genuinely miserable diseases where the bile ducts scar shut and there's nothing approved to stop it. The results, published in the American Journal of Gastroenterology in December 2025, showed meaningful biomarker improvements in inflammation and fibrosis markers, particularly at the higher dose and particularly in patients with moderate to advanced fibrosis. That is a real signal from a real trial. Not a carefully worded press release written to obscure a failure. But "real Phase 2 signal" doesn't write a Phase 3 check, and a pivotal PSC trial would be a multi-year, multi-hundred-million-dollar undertaking that a $14 million market cap was never going to fund on its own. So they sold. The deal and why the spread is as wide as it is The merger was signed July 7, 2026. Chemomab is merging with Scipher Medicine, a private AI company that's been building patient stratification tools for rheumatoid arthritis β€” specifically, trying to predict in advance which patients will actually respond to biologic therapy, which about 70% of RA patients currently don't on first try. The combined thesis is: take nebokitug, which already shows anti-inflammatory and anti-fibrotic activity, and use Scipher's AI platform to select only the RA patients whose biology suggests they'll actually respond to CCL24 blockade. Build a smarter trial than the unselected designs that have been piling up failures in RA drug development for years. It's coherent. Whether it works is a Phase 2 readout that's not expected until the first half of 2028. Anyone who tells you they know right now is full of shit. The deal math: Scipher's convertible note holders end up with roughly 68% of the combined entity; CMMB's current shareholders keep 32%. Concurrently at closing, a minimum $30 million PIPE comes in at a $150 million pre-money valuation, with 100% warrant coverage at 50% of the PIPE price for participating investors β€” which dilutes everyone, but when you run the full math, CMMB's implied per-ADS value lands at approximately $6.08. The PIPE is led by Northpond Ventures, with Khosla Ventures, Blue Owl Healthcare Opportunities, and funds managed by Neuberger Berman alongside. These are not pump shops. They have done real life-science diligence and committed binding capital. That matters. The stock is at $1.93. That's a 68% discount to deal value. The spread exists because this thing has a non-trivial chance of dying in bureaucratic purgatory before it ever closes. Everything standing between you and $6 per ADS The deal targets a Q4 2026 close. That is an aggressive timeline and here is why. First, the SEC needs to review and declare effective an S-4 registration statement for a foreign cross-border merger. For a deal like this, that process realistically runs four to six months from initial filing β€” comments, responses, re-reviews, the whole bureaucratic ballet. If they haven't filed yet, Q4 is optimistic and Q1 2027 is the realistic base case. Second, and this is the opaque one: the deal requires tax rulings from the Israeli Tax Authority on the treatment of company options and shares under Israeli law, plus withholding exemptions for non-Israeli shareholders. The ITA is not known for speed or predictability. This is the single item that differentiates this situation from a normal domestic merger arb, and it's the one that cannot be modeled from the outside. One stuck ruling can delay a closing by months. Third, CMMB needs a shareholder vote. The fun part: they couldn't even assemble a quorum at their April 2026 annual general meeting, which had to be adjourned to May and reconvened. The shareholder base is tiny and disengaged. The board is unanimous, roughly 20% of shareholders have already signed support agreements to vote yes, and getting above a simple majority of the remaining 80% is workable β€” but it is not free. Micro-cap mergers do occasionally die at shareholder votes. Finally, after the vote passes, Israeli company law requires a mandatory 50-day statutory waiting period before the deal can actually close. That clock starts post-vote. It doesn't start now. Stack all of that together and you're parking capital in a barely-liquid stock for five to eight months, bleeding operating losses the entire time, while an Israeli bureaucracy and an SEC comment cycle each run their own course. The insider picture, which is thin CEO and co-founder Adi Mor bought $20,246 worth of shares in late May 2026, right around the same time two directors quietly resigned from the board simultaneously. Twenty thousand dollars from a founder who's run this company for fifteen years and has a decade and a half of accumulated equity is what you do when you want a Form 4 in the filing system without actually putting your ass on the line. It reads as marginal-conviction optics, not a real bet. The simultaneous director departures are a flag that sits there unexplained. Zero insider sells across the past two years β€” that's the best version of this insider story, and it's still not great. The largest known holder is HBM Healthcare Investments, a Swiss healthcare fund that filed a 13D on July 16 disclosing roughly 12.5% of the company. They appear supportive of the transaction. The verdict This is a speculative merger arb, and you should size it exactly like that means. At a 60-65% deal-close probability, the expected value of this position works out to roughly $4.20 per ADS against a $1.93 entry. The science behind nebokitug is real. The PIPE backers have done actual diligence and committed binding capital. The board is unanimous. The spread is genuine and the deal is genuine, and both of those things can simultaneously be true alongside "this has a real chance of dying in an Israeli tax office in ways nobody can model from here." This is not a long-term growth buy and it is not a quick flip β€” the announcement pop happened a month ago and the easy money is gone. It is a patient, sized-for-binary position in a deal that has legitimate upside if the bureaucracy cooperates and real downside if it doesn't. If you go in, go in with money you can afford to have locked up for six to eight months and go in knowing that if the deal breaks, $1.10 is where you're going. If you're not comfortable with that math, the sideline is free. Not financial advice. Do your own research. I hold no position as of this writing. \--- That's approximately 1,350 words β€” tight two-pager for Reddit. Adjust the disclosure at the bottom to match your actual position before posting.

β€’r/pennystocksSee Comment

CMMB rising

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

Only this CMMB garbage is mooning.

Mentions:#CMMB
β€’r/pennystocksSee Comment

CMMB

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

Thoughts on CMMB?

Mentions:#CMMB
β€’r/ShortsqueezeSee Comment

Short CMMB

Mentions:#CMMB
β€’r/ShortsqueezeSee Comment

CMMB short covering.

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

It’s up +60% CMMB put it lol.

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

Is CMMB cash money brothers?

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

CMMB booming this morning

Mentions:#CMMB
β€’r/ShortsqueezeSee Comment

CMMB earnings on Friday

Mentions:#CMMB
β€’r/ShortsqueezeSee Comment

Called three months out…CMMB is next

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

Veru tooks profits around 12.60 went little higher πŸ‘€ Bwv accumulating while others are not low float news april 20 IHSL low float jump into high 80s beginning march can see another pop as well CMMB low float Cathie woods and peter Thiel have also invested

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

CMMB also low float with cathie woods and peter Thiel as investors great tech can jump hard news may be coming as well

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: CMMB. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

CMMB.

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

I am a bot. You submitted a picture of a banned ticker, CMMB. This check will fire if you included unnecessary pictures that have bad phrases or a bad crop with news about cryptocoins, for example. Repost with the useless pictures omitted if you did that. Yell at /u/zjz if it's above 1.5 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

CMMB let’s go!!!

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: CMMB. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

CMMB and MVIS to the moon!!!

Mentions:#CMMB#MVIS
β€’r/wallstreetbetsSee Comment

**Ticker Added CMMB** Spam: True Last Seen Market Cap: 161192600.0 Is SPAC: False Common Word: False

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

$CMMB has interesting volume and price action recently. A lot of chatter on forums and Twitter hinting this one might go!!

Mentions:#CMMB
β€’r/wallstreetbetsSee Comment

CMMB. Is about to explode again.

Mentions:#CMMB
β€’r/StockMarketSee Comment

CMMB πŸš€πŸš€πŸš€πŸš€πŸ¦πŸ¦

Mentions:#CMMB
β€’r/StockMarketSee Comment

CMMB πŸš€πŸš€πŸš€πŸš€πŸš€πŸ¦πŸ¦πŸ¦πŸ¦πŸ¦πŸ¦

Mentions:#CMMB